Financials
Financial year 2025
ComPro Pharma from Sprimont, company number BE0746429351, closed financial year 2025 with a result of € 54,298 after tax. For that financial year ComPro Pharma recorded a gross margin of € 77,795 and equity of € 9,170. Compared with financial year 2024, the result moved from € 56,892 to € 54,298. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 9,170
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 54,298
▼ 5% vs 2024
Profit after tax over the fiscal year.
€ 29,894
▼ 41% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 54,000 paid out
99 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 6,896
▼ 47% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 816
▲ € 813 vs 2024
Loans from banks and other lenders, long and short.
€ 1,139
▼ 43% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 11,754
▼ 27% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 145,500 | € 160,650 | - | - | |
| Gross margin | € 57,173 | € 72,664 | € 75,112 | € 77,795 | ▲ 4% |
| Profit after taxes | € 44,002 | € 56,010 | € 56,892 | € 54,298 | ▼ 5% |
| Equity | € 130,971 | € 6,980 | € 8,872 | € 9,170 | ▲ 3% |
| Total debts | € 33,000 | € 86,367 | € 73,161 | € 67,709 | ▼ 7% |
| Cash | € 149,451 | € 77,293 | € 50,853 | € 29,894 | ▼ 41% |
| Retained profit | € 126,971 | € 2,980 | € 4,872 | € 5,170 | ▲ 6% |
| Dividend | € 0 | € 180,000 | € 55,000 | € 54,000 | ▼ 2% |
| Bank debt | € 88 | € 3 | € 3 | € 816 | ▲ € 813 |
| Balance sheet total | € 163,971 | € 93,347 | € 82,033 | € 76,879 | ▼ 6% |
Key figures of ComPro Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ComPro Pharma?
What happened at ComPro Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 54,298 (▼ 5% vs 2024). Source: NBB ↗
- New establishment in Sprimont. KBO
- Start of the company according to the CBE. KBO
- FABIENNE WIJZEN became a director. NBB
In short
From € 44,002 profit in 2022 to € 54,298 profit in 2025.
Paid € 59,199 in corporate taxes since 2022.
Best year ever: 2024, with € 56,892 profit.
Paid out € 289,000 in dividends to the owners in total.
A new publication or filing at ComPro Pharma? We notify you, reason included.
Follow ComPro PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ComPro Pharma is FABIENNE WIJZEN.
Directors
According to the 2025 annual accounts
FABIENNE WIJZEN
Director
since 2020
Establishments
Establishment units
Physical locations of this company
Rue d'Ogné 36
4140 Sprimont
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0746.429.351
- VAT number
- BE 0746.429.351
- Registered office
- Rue d'Ogné 36, 4140 Sprimont
- Names & denominations
- ComPro Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 21 April 2020
- Peppol
- Active · Active since 7 Nov 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering